Abstract
Engineered T cells that encode transgenic T cell receptors (TCR) or chimeric antigen receptors (CAR) are increasingly being tested is a new modality for cancer immunotherapy. In this presentation we will review emerging patterns of efficacy and toxicity after adoptive cell transfer (ACT), with a focus on blood cancers. Striking efficacy has been observed in acute and chronic B cell leukemia and lymphoma. More unexpectedly, strong antitumor effects are being observed in multiple trials in patients with advanced refractory and relapsed myeloma. In some cases, toxicity has been predicted in preclinical models. In other cases, toxicity was only uncovered after results from Phase 1 clinical trial results were in hand. Onset of toxicity can be immediately observed following infusion of cells or maybe delayed. Toxicity usually occurs coincident with peak (Cmax) levels of adoptively transferred cells. Today with more than 1,000 patients having been infused with genetically engineered human T cells, genotoxicity has not been reported. To date, the induction of irAE appears to be less than with checkpoint therapies, although more experience with ACT is required to determine the ultimate incidence of autoimmune toxicities. Keywords: T-cell receptor (TCR). Disclosures: June, C: Research Funding: Parker Institute for Cancer Immunotherapy, NIH/NCI, Tmunity Therapeutics.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
